4D pharma to Participate in Upcoming Virtual Investor Conferences in September

Rhea-AI Summary

4D pharma (NASDAQ: LBPS) announced its participation in two virtual investor conferences: the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 07:00 ET and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 08:15 ET. Webcasts of these events will be available on the company’s website for 90 days post-event. 4D pharma is a leader in developing Live Biotherapeutics targeting various diseases, backed by proprietary technology and multiple clinical programs.

LEEDS, England--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that 4D pharma management will present at the following virtual investor conferences:

• H.C. Wainwright 23rd Annual Global Investment Conference at 07:00 ET (12:00 BST) on Monday, September 13, 2021
• Oppenheimer Fall Healthcare Life Sciences & MedTech Summit at 08:15 ET (13:15 BST) on Wednesday, September 22, 2021

A webcast of each presentation will be available via the ‘Events’ section of the 4D pharma website at www.4dpharmaplc.com. Archived replays of the webcasts will be available for 90 days following the presentation.

About 4D pharma

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005080/en/

4D pharma

Investor Relations: ir@4dpharmaplc.com

N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Philip Davies / Iqra Amin / James Fischer (Corporate Finance)

Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

Stern Investor Relations, Inc. +1-212-362-1200

Julie Seidel Julie.seidel@sternir.com

Image Box Communications +44 (0)20 8943 4685

Neil Hunter / Michelle Boxall

neil@ibcomms.agency / michelle@ibcomms.agency

Source: 4D pharma

FAQ

What conferences is 4D pharma (LBPS) presenting at in September 2021?

4D pharma (LBPS) is presenting at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021.

What time will 4D pharma's presentations occur?

The presentation at the H.C. Wainwright conference is at 07:00 ET and the Oppenheimer conference at 08:15 ET.

Where can I watch the 4D pharma (LBPS) conference presentations?

The presentations can be viewed via the 'Events' section on 4D pharma's website, with archived replays available for 90 days.

What is 4D pharma's focus in drug development?

4D pharma specializes in developing Live Biotherapeutics, a novel drug class derived from the microbiome, targeting various diseases.

What are some of the clinical programs of 4D pharma (LBPS)?

4D pharma has five clinical programs, including studies targeting solid tumors, asthma, and Irritable Bowel Syndrome (IBS).